Last Update: Aug 03, 2026 An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) ClinicalTrials.gov Identifier: [NCT05939414](https://clinicaltrials.gov/ct2/show/NCT05939414) Novartis Reference Number:CAAA617D12302 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT). All participants will be assessed for eligibility and will undergo baseline disease assessments including a mandatory gallium (68Ga) gozetotide (also known as \\\[68Ga\\\]Ga-PSMA-11) or piflufolastat (18F) ( also known as\\\[18F\\\]DCFPyL) PET/CT scan and CI (i.e., CT/MRI and bone scans). Piflufolastat (18F) PET/CT scan will be performed in countries where it is approved. Stereotactic Body Radiation Therapy (SBRT) will be administered to all metastatic Prostate Cancer (PC) lesions after randomization and before the start of treatment with AAA617 or observation. \* The duration of SBRT procedures is approximately 3 weeks. \* For participants randomized to the investigational arm (AAA617), the treatment duration will be up to 4 cycles of AAA617. For participants randomized to the control arm (observation) the treatment duration will end at the last fraction of SBRT administration. \* The visit frequency will be every week 1 and 3 of each of the 4 cycles and every 16 weeks thereafter (for both arms) until first event of disease progression (RECIST 1.1) \* The study duration is approximately 6.5 years. Condition Oligometastatic Prostate Cancer (OMPC) Phase Phase3 Overall Status Recruiting Number of Participants450 Start Date Mar 12, 2024 Completion Date Oct 03, 2031 Gender Male Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Interventions Drug ### AAA617 Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm ## Eligibility Criteria Key Inclusion criteria: 1\. Histologically confirmed prostate cancer prior to randomization 2\. Participants must have biochemically recurrent disease after definitive treatment to prostate by Radical Prostatectomy ((RP), (alone or with post-operative radiation to prostate bed/pelvic nodes)) or External beam Radiation Therapy (EBRT), (prostate alone or prostate with seminal vesicle and/or pelvic nodes) and/or brachytherapy prior to randomization. Biochemical recurrence (BCR) is defined as: nadir PSA + 2 ng/mL post XRT (if participant received-radiation therapy to intact prostate) and PSA \\> 0.2 ng/mL and rising post RP (with or without post-operation Radiation Therapy (RT)) 3\. Participants must have OMPC with 1-5 PSMA -positive metastatic lesions on screening PSMA PET/CT scan (with either gallium (68Ga) gozetotide or piflufolastat (18F)) as visually assessed by BIRC. For definition of PSMA PET positivity, please refer to Section 8.1 and the Imaging Manual. Metastatic lesions may include regional/pelvic lymph nodes (N1), distant lymph nodes (M1a), bone (M1b), lung and others visceral (M1c) except liver and brain classified using American Joint Committee on Cancer (AJCC) 8. When counting the number of oligometastatic lesions, each lesion is counted as distinct metastasis irrespective of its anatomical location (e.g., one pelvic and one extra-pelvic lymph node will be counted as two metastatic lesions) 4\. At least 1 PSMA-positive lesion must be a distant metastasis (M1) per AJCC8 classification at screening. For AJCC M staging, PSMA PET/CT information should be used 5\. Participants must have a negative CI for M1 disease at screening. Note: \* For a participant not to be eligible, CI positive M1 lesions should be unequivocal in CI scans, i.e., potentially not attributable to findings thought to represent something other than tumor (e.g., degenerative, or post-traumatic changes or Paget's disease in bone lesions). For CI assessments, bone lesions must be assessed by bone scan only and soft tissue lesions must be assessed by CT/MRI scans only at screening. \* Prior knowledge of PSMA PET positivity should not influence the radiologist (reader) in determination of CI positivity. Two different readers will be involved, one reader for PSMA PET/CT scan and one reader for CI: Reader will be blinded to PSMA PET scan results while reading CI scans. Reader should not modify their assessment of CI scans (e.g. changing a lesion previously identified as equivocal in CI to unequivocal) after reading the PSMA PET scan. Similarly, biopsy positivity should not influence the reader in the assessment of CI positivity. More details on the reading paradigm will be provided in the imaging charter \* MRI for radiation treatment planning may show M1 disease but this will not exclude the participant from the study if the lesion is deemed negative per baseline CT or bone scans \* Participants with pelvic disease (N1) seen in CI are allowed if the local spread is below common iliac bifurcation (per AJCC 8 definition of local disease) \* Distant lymph node disease (M1a) that is visible per CI and less than 10mm in the short axis is not exclusionary irrespective of PSMA PET positivity. \* If a previously surgically removed lesion was unequivocal for M1 by bone scan or CT, the participant is not eligible. 6\. All metastatic lesions detected at screening must be amenable to SBRT 7\. Non-castration testosterone level \\>100 ng/dL at screening Key Exclusion criteria: 1\. Participants with de novo OMPC at screening 2\. Unmanageable concurrent bladder outflow obstruction or urinary incontinence at screening. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed 3\. Prior therapy with: 1. ADT (including bilateral orchiectomy) and ARPIs used for metastatic prostate cancer treatment \* Participants who received AR-directed therapy, whether ADT or an ARPI or both, as neoadjuvant or adjuvant therapy as a component of their primary therapy, are eligible provided that they discontinued therapy ≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy. ARPI's as a term includes both contemporary androgen synthesis inhibitors (e.g., abiraterone, galeterone, and orteneronel), and receptor inhibitors (enzalutamide, apalutamide and darolutamide). \* Patients who biochemically relapsed after primary therapy may also have had treatment with AR directed therapy and participants who had SBRT with ADT are also eligible provided that the ARPI +/- ADT or ADT alone was terminated ≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy. \* Participants who received first generation anti-androgens (bicalutamide, flutamide, nilutamide, cyproterone) for biochemical recurrence or adjuvant/neoadjuvant therapy are eligible provided that they discontinued therapy ≥3 months prior to randomization. \* Participants who have discontinued ADT due to disease progression are not eligible (i.e., Castration-Resistant Prostate Cancer (CRPC) participants) 2. Other hormonal therapy. e.g., •Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride), other steroidogenesis inhibitors (aminoglutethimide) if used in the context of prostate cancer treatment. Same medications are allowed if used for other indications: e.g., Benign Prostatic Hyperplasia (BPH), if stopped ≥3 months before randomization. 3. Radiopharmaceutical agents (e.g., Strontium-89, PSMA-targeted radioligand therapy) 4. Immunotherapy (e.g., sipuleucel-T) 5. Chemotherapy, except if administered in the adjuvant/neoadjuvant setting completed \\> 12 months before randomization 6. Any other investigational or systemic agents for metastatic disease 4\. Radiation therapy external beam radiation therapy (EBRT) and brachytherapy within 28 days before randomization 5\. Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, hormonal therapy (see ADT initiation guidance in Section 6.8.2), Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor, biological therapy or investigational therapy 6\. Diagnosed at screening with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease/treatment free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer. 7\. History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants participating in the study such as: \* Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically significant second or third degree Atrioventricular (AV) block without a pacemaker \* History of familial long QT syndrome or known family history of Torsades de Pointe 8\. Participants in immediate need of ADT as assessed by the investigator. Other protocol defined Inclusion/Exclusion may apply. Argentina #### Novartis Investigative Site Recruiting Caba,C1431fwo,Argentina #### Novartis Investigative Site Recruiting CABA,Buenos Aires,C1426anz,Argentina #### Novartis Investigative Site Recruiting CABA,C1181ach,Argentina Australia #### Novartis Investigative Site Recruiting Darlinghurst,New South Wales,2010,Australia #### Novartis Investigative Site Recruiting Adelaide,South Australia,5000,Australia #### Novartis Investigative Site Recruiting Malvern,Victoria,3144,Australia #### Novartis Investigative Site Recruiting Herston,Queensland,4029,Australia Austria #### Novartis Investigative Site Recruiting Linz,4020,Austria #### Novartis Investigative Site Recruiting Vienna,1090,Austria Belgium #### Novartis Investigative Site Recruiting Wilrijk,2610,Belgium #### Novartis Investigative Site Recruiting Aalst,9300,Belgium #### Novartis Investigative Site Recruiting Ghent,9000,Belgium Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,01246 000,Brazil Canada #### Novartis Investigative Site Recruiting Montreal,Quebec,H2x 1r9,Canada #### Novartis Investigative Site Recruiting Montreal,Quebec,H3t 1e2,Canada #### Novartis Investigative Site Recruiting London,Ontario,N6a 4g5,Canada #### Novartis Investigative Site Recruiting Ottawa,Ontario,K1h 8l6,Canada #### Novartis Investigative Site Recruiting Toronto,Ontario,M5g 2m9,Canada #### Novartis Investigative Site Recruiting Calgary,Alberta,T2n 5g2,Canada #### Novartis Investigative Site Recruiting Québec,Quebec,G1j 1z4,Canada #### Novartis Investigative Site Recruiting Halifax,Nova Scotia,B3h 2y9,Canada China #### Novartis Investigative Site Recruiting Beijing,100036,China #### Novartis Investigative Site Recruiting Guangzhou,510060,China #### Novartis Investigative Site Recruiting Shanghai,200127,China Colombia #### Novartis Investigative Site Recruiting Bogota,Cundinamarca,110111,Colombia #### Novartis Investigative Site Recruiting Bogotá,110131,Colombia Czechia #### Novartis Investigative Site Recruiting Ostrava,Poruba,708 52,Czechia #### Novartis Investigative Site Recruiting Olomouc,779 00,Czechia #### Novartis Investigative Site Recruiting Prague,150 06,Czechia France #### Novartis Investigative Site Recruiting Saint-Cloud,Hauts De Seine,92210,France #### Novartis Investigative Site Recruiting Bordeaux,33076,France #### Novartis Investigative Site Recruiting Bron,69677,France #### Novartis Investigative Site Recruiting Clermont-Ferrand,63011,France #### Novartis Investigative Site Recruiting Rouen,76038,France #### Novartis Investigative Site Recruiting Saint-Herblain,44805,France Germany #### Novartis Investigative Site Recruiting Berlin,10249,Germany #### Novartis Investigative Site Recruiting Essen,45147,Germany #### Novartis Investigative Site Recruiting Rostock,18057,Germany #### Novartis Investigative Site Recruiting Aachen,52074,Germany #### Novartis Investigative Site Recruiting Augsburg,86179,Germany #### Novartis Investigative Site Recruiting Cologne,North Rhine-Westphalia,50937,Germany #### Novartis Investigative Site Recruiting Munich,Bavaria,81377,Germany #### Novartis Investigative Site Recruiting Münster,48149,Germany Greece #### Novartis Investigative Site Recruiting Thessaloniki,540 07,Greece #### Novartis Investigative Site Recruiting Athens,11528,Greece Hungary #### Novartis Investigative Site Recruiting Budapest,H-1083,Hungary #### Novartis Investigative Site Recruiting Budapest,H 1122,Hungary #### Novartis Investigative Site Recruiting Debrecen,Hajdu Bihar Megye,4032,Hungary Israel #### Novartis Investigative Site Recruiting Haifa,3109601,Israel #### Novartis Investigative Site Recruiting Jerusalem,9112001,Israel #### Novartis Investigative Site Recruiting Tel Aviv,6423906,Israel #### Novartis Investigative Site Recruiting Beersheba,8457108,Israel #### Novartis Investigative Site Recruiting Petah Tikva,4941492,Israel Italy #### Novartis Investigative Site Recruiting Genova,GE,16132,Italy #### Novartis Investigative Site Recruiting Rozzano,MI,20089,Italy #### Novartis Investigative Site Recruiting Roma,RM,00168,Italy #### Novartis Investigative Site Recruiting Negrar,VR,37024,Italy #### Novartis Investigative Site Recruiting Cona,FE,44124,Italy #### Novartis Investigative Site Recruiting Pisa,PI,56126,Italy #### Novartis Investigative Site Recruiting Milan,MI,20141,Italy Japan #### Novartis Investigative Site Recruiting Fukuoka,811-0213,Japan #### Novartis Investigative Site Recruiting Fukuoka,812-0033,Japan #### Novartis Investigative Site Recruiting Kobe,Hyōgo,6500047,Japan #### Novartis Investigative Site Recruiting Chuo Ku,Tokyo,1040045,Japan #### Novartis Investigative Site Recruiting Fukuoka,8128582,Japan #### Novartis Investigative Site Recruiting Fukushima,9601295,Japan #### Novartis Investigative Site Recruiting Kyoto,6068507,Japan #### Novartis Investigative Site Recruiting Ishikawa,9208641,Japan #### Novartis Investigative Site Recruiting Kashiwa,Chiba,277-8577,Japan #### Novartis Investigative Site Recruiting Sapporo,Hokkaido,060-8648,Japan #### Novartis Investigative Site Recruiting Yokohama,Kanagawa,236-0004,Japan Malaysia #### Novartis Investigative Site Recruiting Petaling Jaya,Selangor,46050,Malaysia #### Novartis Investigative Site Recruiting Kuala Lumpur,59100,Malaysia Mexico #### Novartis Investigative Site Recruiting Mexico City,Mexico City,14050,Mexico #### Novartis Investigative Site Recruiting Huxquilucan,52763,Mexico Netherlands #### Novartis Investigative Site Recruiting Amsterdam,1066 cx,Netherlands Puerto Rico #### VA Caribbean Healthcare System Recruiting San Juan,00921,Puerto Rico ###### Bartolo Santiago-Delgado ###### Sara Fuentes-Medina Phone: [+17876417582#10393](tel:+17876417582#10393) Email: Singapore #### Novartis Investigative Site Recruiting Singapore,168583,Singapore #### Novartis Investigative Site Recruiting Singapore,119074,Singapore Slovakia #### Novartis Investigative Site Recruiting Bratislava,83310,Slovakia #### Novartis Investigative Site Recruiting Nitra,949 01,Slovakia #### Novartis Investigative Site Recruiting Trenčín,911 01,Slovakia #### Novartis Investigative Site Recruiting Košice,041 91,Slovakia Spain #### Novartis Investigative Site Recruiting El Palmar,Murcia,30120,Spain #### Novartis Investigative Site Recruiting Madrid,28040,Spain #### Novartis Investigative Site Recruiting Madrid,28041,Spain #### Novartis Investigative Site Recruiting Barcelona,08036,Spain #### Novartis Investigative Site Recruiting Valencia,46010,Spain #### Novartis Investigative Site Recruiting Granada,Andalusia,18014,Spain #### Novartis Investigative Site Recruiting Barcelona,Catalonia,08025,Spain #### Novartis Investigative Site Recruiting Seville,41013,Spain #### Novartis Investigative Site Recruiting L'Hospitalet de Llobregat,Barcelona,08907,Spain Switzerland #### Novartis Investigative Site Recruiting Geneva,1211,Switzerland #### Novartis Investigative Site Recruiting Lucerne,6006,Switzerland #### Novartis Investigative Site Recruiting Zurich,8063,Switzerland Taiwan #### Novartis Investigative Site Recruiting Taipei,103616,Taiwan #### Novartis Investigative Site Recruiting Taipei,11217,Taiwan #### Novartis Investigative Site Recruiting Taipei,10002,Taiwan #### Novartis Investigative Site Recruiting Taoyuan,33305,Taiwan United Kingdom #### Novartis Investigative Site Recruiting Bristol,Avon,Bs2 8ed,United Kingdom #### Novartis Investigative Site Recruiting Coventry,Cv2 2dx,United Kingdom #### Novartis Investigative Site Recruiting London,Nw3 2qg,United Kingdom #### Novartis Investigative Site Recruiting Guildford,Surrey,Gu2 7xx,United Kingdom #### Novartis Investigative Site Recruiting London,Sw3 6jj,United Kingdom United States #### BAMF Health Recruiting Grand Rapids,Michigan,49503,United States ###### Brandon Mancini ###### Kamara Kam Bailey Email: #### Mayo Clinic Rochester Recruiting Rochester,Minnesota,55905,United States ###### Ryan Phillips ###### Takeru Walleser Phone: [507-538-2155](tel:507-538-2155) Email: #### Dayton Physicians Recruiting Kettering,Ohio,45409,United States ###### Lynette Tipton Phone: [937-771-2287](tel:937-771-2287) Email: ###### Trevor Bluemel #### Oregon Urology Institute Recruiting Springfield,Oregon,97477,United States ###### Bryan Mehlhaff ###### Victoria Evans Phone: [541-284-5508](tel:541-284-5508) Email: #### Highlands Oncology Group Recruiting Fayetteville,Arkansas,72703,United States ###### Joseph Thaddeus Beck ###### Tina Patrick Phone: [+1 479 878 7098]() Email: #### Cancer Specialists of North Florida Recruiting Jacksonville,Florida,32256,United States ###### Bhaloo Desai Email: ###### Richard Cassidy #### Johns Hopkins Kimmel Com Cancer Ctr Recruiting Baltimore,Maryland,21231,United States ###### Ana Kiess ###### Dana Kaplan Email: #### Virginia Oncology Associates Recruiting Norfolk,Virginia,23502,United States ###### Amber Ingram Phone: [757-466-8683](tel:757-466-8683) Email: ###### Mark Fleming #### Stanford University Recruiting Palo Alto,California,94304,United States ###### Camellia Djebroun Phone: [605-498-6000](tel:605-498-6000) Email: ###### Mallika Marar #### Woodlands Medical Specialists Recruiting Pensacola,Florida,32503,United States ###### Jacqueline Martin Email: ###### Michael Poiesz #### University of Kansas Hospital Recruiting Kansas City,Kansas,66160,United States ###### Daniel Rivera Email: ###### Xinglei Shen #### Mary Bird Perkins Cancer Center Recruiting Baton Rouge,Louisiana,70809,United States ###### Courtney Hill Phone: [225-215-1353](tel:225-215-1353) Email: ###### Victor Lin #### University of Maryland Medical Ctr Recruiting Baltimore,Maryland,21201,United States ###### Arif Hussain ###### Dawn Barth Phone: [410-328-8667](tel:410-328-8667) Email: #### Vanderbilt University Medical Center Recruiting Nashville,Tennessee,37232,United States ###### Kerry Schaffer ###### Laura Diedrich Email: #### Rio Grande Urology Recruiting El Paso,Texas,79912,United States ###### Jameson T Mendel ###### Paola Delgado Email: #### Blue Ridge Cancer Center Recruiting Wytheville,Virginia,24382,United States ###### Dana Selvia Email: ###### David Buck #### UCSF Recruiting San Francisco,California,94115,United States ###### Brittany Liu Phone: [415-514-6241](tel:415-514-6241) Email: ###### Steven Seyedin #### Univ of Texas Southwest Med Center Recruiting Dallas,Texas,75390-9034,United States ###### Amy Rowell Phone: [214-645-5905](tel:214-645-5905) Email: ###### Kevin Courtney #### University of Chicago Recruiting Chicago,Illinois,60637,United States ###### Ashley Page Phone: [773-702-8582](tel:773-702-8582) Email: ###### Mohammad Atiq #### The Cancer Institute of Alexian Brothers Recruiting Elk Grove,Illinois,60007,United States ###### Khalada Ahmad Email: #### Dana Farber Cancer Institute Recruiting Boston,Massachusetts,02115,United States ###### Mai Anh Huynh ###### Sinead Christensen Email: #### VA Palo Alto Health Care System Recruiting Palo Alto,California,94304-1207,United States ###### Minal Vasanawala ###### Niko Del Mar Phone: [650-493-5000](tel:650-493-5000) Email: #### Rocky Mountain Cancer Centers Recruiting Denver,Colorado,80218,United States ###### Allen Cohn ###### Jennifer Hege Phone: [303-338-4876](tel:303-338-4876) Email: #### VA Greater LA Healthcare System Recruiting Los Angeles,California,90073,United States ###### Matthew Rettig ###### Samantha Tran Phone: [310-478-3711](tel:310-478-3711) Email: #### Associated Med Professionals of NY Recruiting Syracuse,New York,13210,United States ###### Alex Bart Email: ###### Steven Finkelstein #### Carolina Urologic Research Center Recruiting Myrtle Beach,South Carolina,29572,United States ###### Neal D Shore ###### Rebecca Floyd Phone: [843-839-1679](tel:843-839-1679) Email: #### Wash U School of Medicine Recruiting St Louis,Missouri,63110,United States ###### Collin Welch Email: ###### Hiram Gay #### Piedmont Healthcare Recruiting Atlanta,Georgia,30318,United States ###### Adam Nowlan ###### Sharon Joseph #### East Carolina University Recruiting Greenville,North Carolina,27858,United States ###### Andrew Ju ###### Kayleigh Nunley Phone: [252-744-0456](tel:252-744-0456) Email: #### Montefiore Hospital Recruiting The Bronx,New York,10467 2490,United States ###### Benjamin A Gartrell ###### Darciann O Sullivan Phone: [267-455-2717](tel:267-455-2717) Email: #### East Jefferson Hospital Recruiting Metairie,Louisiana,70006,United States ###### Alexandra Lieberman Email: ###### Alton Oliver Sartor #### Beth Israel Deaconess Med Ctr Recruiting Boston,Massachusetts,02215,United States ###### David J Einstein ###### Stephen Duggan Email: #### William Beaumont Hospital Recruiting Royal Oak,Michigan,48073,United States ###### Andrew Thompson ###### Jennifer Murray Phone: [248-551-6485](tel:248-551-6485) Email: #### Unity Point Clinic Recruiting Des Moines,Iowa,50323,United States ###### Mark Kellerman ###### Tracy Sarin Email: #### Memorial Sloan Kettering Cancer Ctr Recruiting New York,New York,10065,United States ###### Daniel Gorovets ###### Viktoria Matessi Phone: [212-639-3854](tel:212-639-3854) Email: #### The Urology Center PC DBA UroHealth Partners Recruiting Omaha,Nebraska,68114,United States ###### Amy Nelson Email: ###### Andrew Trainer #### St Louis University Recruiting St Louis,Missouri,63104,United States ###### Medhat Osman ###### Sabrina Abdullaeva Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: